Study Status: Withdrawn
Recruit Status: Withdrawn
Study Type: Interventional
Official Title: Treatment of Transient Myeloproliferative Disorder (TMD) in Children With Down Syndrome (DS)
Brief Summary:
RATIONALE: Drugs used in chemotherapy, such as cytarabine, work in different ways to stop the growth of abnormal cells, either by killing the cells or by stopping them from dividing. Giving low-doses of cytarabine may be an effective treatment for Down syndrome and transient myeloproliferative disorder. Sometimes the disease may not need treatment until it progresses. In this case, observation may be sufficient.
PURPOSE: This phase III trial is studying low-dose cytarabine to see how well it works in treating infants with Down syndrome and transient myeloproliferative disorder.